Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Solid Tumors With PIK3Ca Mutation”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175
What this trial is testing

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)UnknownNCT04073680
What this trial is testing

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Who this might be right for
Breast CancerEndometrial CancerLung Cancer+2 more
Petra Pharma 60
Early research (Phase 1)Looking for participantsNCT07383506
What this trial is testing

Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Who this might be right for
PIK3CA MutationsAdvanced Solid Tumors, AdultEndometrial Cancer+2 more
Cogent Biosciences, Inc. 90
Early research (Phase 1)Study completedNCT01226316
What this trial is testing

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Who this might be right for
Advanced Solid MalignancySafety and TolerabilityPharmacokinetics+11 more
AstraZeneca 285
Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Testing effectiveness (Phase 2)Looking for participantsNCT05768139
What this trial is testing

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Who this might be right for
Breast CancerSolid Tumors, Adult
Eli Lilly and Company 880
Early research (Phase 1)Active Not RecruitingNCT04192981
What this trial is testing

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

Who this might be right for
Brain MetastasesLeptomeningeal Metastasis
Memorial Sloan Kettering Cancer Center 21
Early research (Phase 1)Active Not RecruitingNCT06239467
What this trial is testing

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Who this might be right for
Advanced CancerBreast CancerAdvanced Solid Tumors+1 more
OnKure, Inc. 200
Early research (Phase 1)Study completedNCT04344795
What this trial is testing

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Who this might be right for
Solid TumorColorectal CancerNon Small Cell Lung Cancer+6 more
Tempest Therapeutics 89
Early research (Phase 1)Study completedNCT01219699
What this trial is testing

BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Who this might be right for
Advanced Solid Tumors With an Alteration of the PIK3CA GeneEstrogen Receptor Positive Breast Cancer
Novartis Pharmaceuticals 221
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07679269
What this trial is testing

Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
Novartis Pharmaceuticals 51
Testing effectiveness (Phase 2)Study completedNCT06132932
What this trial is testing

WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations

Who this might be right for
PIK3CA Mutation-Related Tumors
Shanghai Jiatan Pharmatech Co., Ltd 38
Testing effectiveness (Phase 2)Study completedNCT02449538
What this trial is testing

Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors

Who this might be right for
Solid Tumor
Samsung Medical Center 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT03994796
What this trial is testing

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Who this might be right for
CDK Gene MutationMetastatic Malignant Neoplasm in the BrainMetastatic Malignant Solid Neoplasm+4 more
Alliance for Clinical Trials in Oncology 50
Testing effectiveness (Phase 2)WithdrawnNCT01501604
What this trial is testing

BKM120 in Cancers With PIK3CA Activating Mutations

Who this might be right for
Lung CancerBreast CancerColorectal Cancer+2 more
Massachusetts General Hospital
Early research (Phase 1)Study completedNCT01473095
What this trial is testing

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Who this might be right for
Solid TumorMalignant LymphomaTumor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 120
Testing effectiveness (Phase 2)Ended earlyNCT01708161
What this trial is testing

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

Who this might be right for
PIK3CA Mutated Advanced Solid TumorsPIK3CA Amplified Advanced Solid Tumors
Novartis Pharmaceuticals 47
Early research (Phase 1)Looking for participantsNCT05216432
What this trial is testing

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Who this might be right for
PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc. 930
Not applicableStudy completedNCT02449564
What this trial is testing

The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors

Who this might be right for
Solid Tumor
Samsung Medical Center 5
Early research (Phase 1)Ended earlyNCT02761694
What this trial is testing

Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)

Who this might be right for
CancerSolid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 78
Next Page